All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Does Tirzepatide Lower Blood Pressure? What the Label and Trials Say

Tirzepatide is not approved to treat blood pressure. Neither label lists it as a use, and SURMOUNT-1 reports cardiometabolic gains alongside weight loss.

By FormBlends Editorial Research|Source reviewed by FormBlends Editorial Standards Team|

Source Reviewed

Written by FormBlends Editorial Research ยท Checked against primary sources by FormBlends Editorial Standards Team

Does Tirzepatide Lower Blood Pressure? What the Label and Trials Say custom 2026 header image for GLP-1 Weight Loss
Custom header image for Does Tirzepatide Lower Blood Pressure? What the Label and Trials Say, GLP-1 Weight Loss, and better treatment decision-making.
In This Article

This article is part of our GLP-1 Weight Loss collection. See also: Provider Comparisons | Peptide Guides

See your GLP-1 options in about 2 minutes. Free and private. See my options →

Tirzepatide is not a blood pressure drug, and neither label lists blood pressure as a use. The main SURMOUNT-1 paper does report better heart and metabolic measures, blood pressure among them, in people who lost weight on the drug. We do not print a blood pressure number here because it is not in our verified source list. If you take a blood pressure pill, tell your prescriber before you start. Read our tirzepatide guide for the basics first.

Key takeaways

  • Zepbound is approved for chronic weight management and for obstructive sleep apnea with obesity; Mounjaro is approved for type 2 diabetes. Neither is approved to lower blood pressure.
  • SURMOUNT-1 reported better heart and metabolic measures as secondary outcomes alongside a mean weight loss of 15.0% to 20.9% over 72 weeks.
  • The Zepbound label's adverse reaction table includes low blood pressure (hypotension) as a reported reaction, and the label warns that vomiting and diarrhea can cause fluid loss.
  • Neither label lists high blood pressure as a common adverse reaction.
  • Any change to a blood pressure medicine while on tirzepatide is a prescriber decision.

Does tirzepatide lower blood pressure?

The short answer is that the labels do not claim it, and the trials were not built to prove it. Tirzepatide's approved uses are weight management, sleep apnea with obesity, and type 2 diabetes. In SURMOUNT-1, blood pressure was one of several heart and metabolic measures tracked as a secondary outcome. The authors reported gains in those measures for people on tirzepatide compared with placebo. Weight loss in that trial was large, which is the most likely reason for those changes, but the trial cannot separate the drug's direct effects from the effect of losing weight.

QuestionWhat the sources say
Is tirzepatide approved to treat high blood pressure?No. Zepbound: chronic weight management (November 8, 2023) and moderate to severe obstructive sleep apnea with obesity (December 20, 2024). Mounjaro: type 2 diabetes (May 13, 2022).
Did SURMOUNT-1 measure blood pressure?Yes, as a secondary cardiometabolic measure; the publication reports improvements with tirzepatide versus placebo.
Does this page print the blood pressure change?No. That number is not in our verified list, so we do not print it.
Is low blood pressure on the label?Yes. Hypotension appears in the Zepbound adverse reaction table; the label does not describe it as one of the most common reactions.
Is high blood pressure on the label?No, it is not listed as a common adverse reaction on either label.

Source: Zepbound and Mounjaro prescribing information (DailyMed); SURMOUNT-1, Jastreboff et al., NEJM 2022.

How much weight did SURMOUNT-1 participants lose?

Because these changes track with weight loss, the weight numbers are the ones worth knowing. SURMOUNT-1 enrolled 2,539 adults with obesity or overweight without diabetes and followed them for 72 weeks.

Check your GLP-1 eligibility

Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.

Try the BMI Calculator →
ArmMean weight change at 72 weeksLost at least 5%Lost at least 20%
Placebo-3.1%35%3%
Tirzepatide 5 mg-15.0%85%Not reported in the summary
Tirzepatide 10 mg-19.5%89%50%
Tirzepatide 15 mg-20.9%91%57%

Source: SURMOUNT-1, Jastreboff et al., NEJM 2022 (treatment-regimen estimand).

The trial also reported that the most common adverse events were gastrointestinal, mostly mild to moderate, and mostly during dose escalation.

Can tirzepatide cause low blood pressure?

It can, and the label says so in two ways. First, hypotension, which means low blood pressure, appears in the Zepbound adverse reaction table as a reaction reported more often with the drug than with placebo. It is not on the label's list of the most common reactions, which are stomach effects, injection site reactions, fatigue, hypersensitivity, burping, hair loss and reflux.

Second, the label warns about dehydration. Nausea, vomiting and diarrhea are the most common reactions, and the label links fluid loss from these events to acute kidney injury. Fluid loss is also a common cause of feeling faint or dizzy when you stand. If you get lightheaded, especially during a dose increase or a stomach bug, call your prescriber. Drink fluids as they advise. Do not skip or lower a blood pressure pill on your own.

If you already take a blood pressure medicine, weight loss can change how much of it you need. The tirzepatide label does not give a rule for that. It is a prescriber decision, so bring home readings to your visits if you have a cuff.

Does tirzepatide cause high blood pressure?

High blood pressure is not listed as a common adverse reaction on the Zepbound or Mounjaro label. In SURMOUNT-1 the heart and metabolic measures got better, not worse. What both labels do note is a small average rise in heart rate with tirzepatide; the label describes it as a mean increase of a few beats per minute and says its clinical relevance is uncertain. A faster pulse is not the same as higher blood pressure, but if you feel palpitations, that is worth a call.

Heart safety: what SURPASS-4 showed

People with high blood pressure often ask about heart risk more broadly. SURPASS-4 compared tirzepatide with insulin glargine in adults with type 2 diabetes and high cardiovascular risk. The trial found no increase in major adverse cardiovascular events with tirzepatide. That is a safety finding, not proof of heart benefit, and it was in people with diabetes rather than in a blood pressure population.

What this means for compounded tirzepatide

All of the numbers above come from branded tirzepatide used in trials. Compounded tirzepatide is not FDA approved, is not interchangeable with Zepbound or Mounjaro, and has no trial data of its own. The same label cautions still apply: tell your prescriber about every blood pressure medicine, watch for dizziness during dose steps, and report fluid loss. Prescriptions for FormBlends compounded tirzepatide are written by independent, state-licensed clinicians of Recess MD LLC, who decide whether it is appropriate for you. See pricing or begin the assessment.

Frequently Asked Questions

Does tirzepatide lower blood pressure?

It is not approved for that, and the label makes no such claim. SURMOUNT-1 reported better heart and metabolic measures, including blood pressure, along with large weight loss. The exact change is not in our verified sources, so this page does not print it.

Can tirzepatide cause low blood pressure?

Yes, hypotension is listed in the Zepbound adverse reaction table, though it is not among the most common reactions. Fluid loss from vomiting or diarrhea can also lower blood pressure. Call your prescriber if you feel faint or dizzy.

Does tirzepatide cause high blood pressure?

High blood pressure is not listed as a common adverse reaction on either label. The label does note a small average rise in heart rate. Report palpitations or a sustained fast pulse to your prescriber.

Can I take tirzepatide if I have high blood pressure?

Many people with high blood pressure took tirzepatide in the trials, and Zepbound's weight management indication covers adults with a BMI of 27 or higher plus a weight-related condition. Whether it is right for you, and whether your blood pressure medicine needs to change, is a prescriber decision.

Sources

  1. Zepbound (tirzepatide) prescribing information, DailyMed, National Library of Medicine, revised 08/2026.
  2. Mounjaro (tirzepatide) prescribing information, DailyMed, National Library of Medicine, revised 08/2026.
  3. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), Jastreboff et al., New England Journal of Medicine, 2022.
  4. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4), Del Prato et al., The Lancet, 2021.
  5. SURMOUNT-1 study record (NCT04184622), ClinicalTrials.gov.

Next steps

Related reading: tirzepatide and heart palpitations, Zepbound and dizziness, and does tirzepatide help with inflammation. Browse the tirzepatide hub for every other tirzepatide question. Talk to a clinician before you start or change any blood pressure medicine. Compounded tirzepatide is not FDA approved and is not interchangeable with Zepbound or Mounjaro; a licensed provider decides whether it is appropriate for you.

See your options in about 2 minutes

Take the free quiz and see what fits you. Quick, private, and no commitment to continue.

See my options →

Research Snapshot

Provider comparison
Page type
Provider comparison
FormBlends review
Last reviewed
2026-09-09
FormBlends review
FormBlends official source
Official source
Found official source
Official source
Mounjaro evidence source
Official source
Tirzepatide evidence source
Official source
Zepbound evidence source
Official source
Before you act
Check the current prescribing information, regulatory status, and trial source before treating an investigational or newly approved medication as interchangeable with an established therapy.
Check before ordering

Regulatory status, labels, trial records, and sponsor updates can change quickly for obesity-drug pipeline pages. This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision. Last page review: 2026-09-09.

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

PubMed evidence trail

Research sources used to frame this page

For Does Tirzepatide Lower Blood Pressure? What the Label and Trials Say, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Randomized trialTirzepatide evidence2022

Tirzepatide Once Weekly for the Treatment of Obesity

Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.

PubMed

Randomized trialTirzepatide evidence2024

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction

Used for continuation, stopping, and maintenance questions after initial weight loss.

PubMed

Randomized trialTirzepatide evidence2025

Tirzepatide for Obesity Treatment and Diabetes Prevention

Supports newer discussion of obesity treatment and diabetes-prevention outcomes.

PubMed

Systematic reviewGLP-1 class evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.

PubMed

Systematic reviewGLP-1 class evidence2025

Discontinuing glucagon-like peptide-1 receptor agonists and body habitus

Used for pages discussing stopping therapy, weight regain, and long-term planning.

PubMed

Systematic reviewGLP-1 class evidence2025

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition

Supports body-composition, lean-mass, and metabolic-risk context.

PubMed

Systematic reviewObesity pharmacotherapy evidence2025

Emerging pharmacotherapies for obesity: A systematic review

Broad context for new and established obesity-drug categories.

PubMed

ReviewObesity pharmacotherapy evidence2026

Glucagon-like receptor agonists and next-generation incretin-based medications

Current review for incretin-based obesity medications and cardiometabolic effects.

PubMed

Systematic reviewObesity pharmacotherapy evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

Used as a class-level evidence anchor when no more specific citation group matches.

PubMed

Continue with decision-grade research

Compare the options behind this question

These pages separate verified facts, commercial terms, and unresolved claims so you can check the evidence before choosing a provider.

GLP-1 decision path

Use this page to decide if a provider review is the right next step

Direct answer

Does Tirzepatide Lower Blood Pressure? What the Label and Trials Say research is most useful when it helps you compare eligibility, expected results, side effects, cost, and the supervision needed before treatment.

Evidence check

The strongest GLP-1 pages connect the practical answer to clinical trials, FDA labeling where applicable, and real access constraints.

Safety check

A licensed clinician still needs to review health history, contraindications, current medications, side effects, and dose escalation.

Next step

When the page matches your goal, continue into the FormBlends get-started flow so the intake can route you toward the right prescription review path.

Original tools and data

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

Editorial refresh

Practical 2026 note for Does Tirzepatide Lower Blood Pressure? What the Label and Trials Say

Does Tirzepatide Lower Blood Pressure? What the Label and Trials Say now carries extra 2026 context around tirzepatide, cash-pay pricing, safety signals, lower, blood, pressure, because those are the subtopics readers tend to compare before they trust a medical or wellness recommendation.

Instead of adding filler, this page keeps the named treatment terms, practical verification points, and next-step questions close to does tirzepatide lower blood pressure.

Readers should use the section to check current eligibility, pharmacy or provider policies, and safety questions with a licensed professional before acting.

Does Tirzepatide Lower Blood Pressure? What the Label and Trials Say custom 2026 image for glp-1 weight loss on FormBlends

Custom 2026 image for Does Tirzepatide Lower Blood Pressure? What the Label and Trials Say, glp-1 weight loss, and better treatment decision-making.

Image description: Unique image for this page covering Does Tirzepatide Lower Blood Pressure? What the Label and Trials Say, glp-1 weight loss, safety, cost, provider selection, and patient decision-making.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by FormBlends Editorial Research

Prepared by FormBlends Editorial Research. Claims are checked against primary regulatory, trial, label, and public-health sources where available. Reviewed against primary medical, regulatory, and trial sources for accuracy, sourcing, and patient-safety framing.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded semaglutide first month $99, then $190 per month, shipping included.

Tirzepatide evidence guide

Tirzepatide: how it works, trial results, dosing and side effects

Start with the evidence guide before comparing doses, prices or providers. It covers the SURMOUNT trial results by dose, the label dosing schedule, side-effect rates, FDA approvals, and what compounded tirzepatide is and is not.

Read the tirzepatide guide โ†’

Next Best Reads

FormBlends for iPhone

Shot days, doses and progress in one place

The free FormBlends iPhone app tracks GLP-1 doses, shot-day reminders, weight trends, meals and private progress photos.

Free Tools

Provider-informed calculators to support your weight loss journey.